[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gestational-diabetes-mellitus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gestational-diabetes-mellitus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,16,0,[8,44,69,102,126,155,179,198,224,245,273,295,318,339,369,389],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100605165","home-ultrasound-in-routine-high-risk-care-of-patients-with-gestational-diabetes-mellitus-gdm-100605165",false,"NCT07158970","Home-Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus (GDM)","Effect of Home Ultrasound in Routine High-Risk Care of Patients With Gestational Diabetes Mellitus","Inclusion Criteria:\n\n* Singleton pregnancy\n* GDM diagnosed by OGTT or glucose monitoring\n* Hebrew speaking\n* Compatible cellphone\n\nExclusion Criteria:\n\n* Pregestational diabetes\n* Fetal anomalies\u002Fgenetic abnormalities\n* Multifetal pregnancy\n* Late GDM diagnosis (after 34 weeks)","FEMALE","18 Years","51 Years",{"count":20,"type":21},90,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study evaluates the impact of incorporating home-ultrasound (home-US) devices into telemedicine care for patients with gestational diabetes mellitus (GDM). The study will compare satisfaction, clinical outcomes, and healthcare costs between standard high-risk pregnancy care and care augmented by home-US.",[27],"Gestational Diabetes Mellitus",[29,30],"home ultrasound","telemedicine","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-03-01",{"date":39,"type":21},"2027-11-01",{"name":41,"class":42},"Wolfson Medical Center","OTHER_GOV",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":53,"minAge":4,"maxAge":17,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":43},"100410199","the-next-generation-longitudinal-birth-cohort-diabetes-study-100410199","NCT04621396","The Next Generation Longitudinal Birth Cohort Diabetes Study","Genetic and Environmental Influences on Development of Type 2 Diabetes in Childhood: The Next Generation Longitudinal Birth Cohort.","NextGen","Inclusion Criteria:\n\n* Pregnant women with type 2 diabetes, gestational diabetes, or no diabetes.\n* From self-identified Indigenous heritage (e.g., Cree, Oji-Cree, Métis, Anishinaabe, etc.).\n* Are delivering and residing in Manitoba.\n* Mother\u002FFather and children must be biological family members.\n\nExclusion Criteria:\n\n* Mothers or children with type 1 diabetes.\n* Residing outside of Manitoba.",true,"ALL",{"count":55,"type":21},600,"OBSERVATIONAL","The overall aim of this project is to understand the independent roles of maternal factors, intrauterine exposures, genetic factors, and postnatal environment on the development of obesity and youth-onset type 2 diabetes (T2D) in childhood.",[59,27],"Type 2 Diabetes","2026-06-30",{"date":34,"type":35},{"date":63,"type":35},"2013-09",{"date":65,"type":21},"2028-12",{"name":67,"class":68},"University of Manitoba","OTHER",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":101},"100550351","phase-4-decide-a-comparative-effectiveness-trial-of-metformin-versus-insulin-for-the-treatment-of-gestational-diabetes-100550351","NCT06445946","DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes","DECIDE","Inclusion Criteria:\n\n* Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age.\n* Age 18 years or older\n* Gestational age at randomization between 20 0\u002F7 - 33 6\u002F7 weeks based on project gestational age.\n* GDM diagnosis less than or equal to 33 6\u002F7 weeks based on project gestational age.\n* Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record.\n* Patient willingness and ability to attend 2-year follow-up visit.\n\nExclusion criteria:\n\n* Renal disease (serum creatinine \\>1.3 mg\u002FdL) due to the potential impact of metformin on renal function.\n* Major structural malformation of the fetus.\n* Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening.\n* Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and\u002For anaphylaxis.\n* For individuals with GDM diagnosed \\\u003C20 0\u002F7 weeks, documented A1c ≥\\>6.5% within prior 6 months.\n* Pregestational diabetes documented in the medical record or prior A1c\\>= 6.5%\n* Fasting hyperglycemia \\>115 mg\u002Fdl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia).\n* Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years).\n* Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff.\n* Language barrier (appropriate translation resources unavailable at the site)\n* Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.",{"count":78,"type":21},1572,[80],"PHASE4","This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin.\n\nThis study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.",[27,83],"Pregnancy, High Risk",[85,86,87,88,89,90,91],"Insulin","Pregnancy","Glycemic control","Metformin","Gestational diabetes","Diabetes","Adverse pregnancy outcomes","2026-06-24",{"date":94,"type":35},"2026-06-25",{"date":96,"type":35},"2024-08-01",{"date":98,"type":21},"2030-12",{"name":100,"class":68},"Ohio State University",24,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":43},"100549615","the-impact-of-continuous-glucose-monitoring-on-maternal-and-infants-outcomes-in-gestational-diabetes-100549615","NCT06436326","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes","The Impact of Continuous Glucose Monitoring on Maternal and Infant's Outcomes in Gestational Diabetes: Testing the Moderating Effects of Socioeconomic and Cultural Factors","Inclusion Criteria:\n\n* Aged 18 years or above\n* Pregnant women diagnosed with gestational diabetes mellitus\n* Those who are willing to participate in this study\n\nExclusion Criteria:\n\n* Those who have been diagnosed with diabetes mellitus \"before pregnancy\"\n* Those whose skin is likely allergic to some materials such as tapes (signs and symptoms such as redness, swelling, itching, painful, presenting blisters or rashes caused by wearing breathable tapes, patches, etc.)\n* Those who is with abnormal coagulation function",{"count":110,"type":21},120,[24],"This study will discuss the impact of continuous glucose monitoring on maternal and infant's outcomes in gestational diabetes mellitus, and test the moderating effect of socioeconomic and cultural factors (dietary habits, socioeconomic status and income).",[27,114],"Continuous Glucose Monitoring",[27,114,116],"Health Interventions","2026-06-17",{"date":119,"type":35},"2026-06-22",{"date":121,"type":35},"2024-08-22",{"date":123,"type":21},"2027-12-31",{"name":125,"class":68},"National Taiwan University Hospital",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":22,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":146,"lastUpdatePostDateStruct":147,"startDateStruct":149,"completionDateStruct":151,"leadSponsor":153,"locationsCount":4},"100643803","nutrition-counseling-diet-quality-and-advanced-glycation-end-products-in-gestational-diabetes-100643803","NCT07636577","Nutrition Counseling, Diet Quality, and Advanced Glycation End Products in Gestational Diabetes","The Relationship Between Nutrition Counseling in Gestational Diabetes Mellitus and Diet Quality and Advanced Glycation End Products","Inclusion Criteria:\n\n* Pregnant women aged 18 to 35 years\n* Singleton and first pregnancy\n* Gestational age between 24 and 28 weeks at enrollment\n* Diagnosis of gestational diabetes mellitus or normal glucose tolerance\n* Not using insulin therapy\n* Stopped smoking at least 3 months before enrollment and not using alcohol\n* Willingness to participate in the study\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Current use of insulin therapy\n* Active smoking\n* Alcohol use\n* Refusal or inability to provide written informed consent","35 Years",{"count":135,"type":21},48,[24],"This study will evaluate the relationship between structured nutrition counseling, diet quality, and advanced glycation end products in pregnant women with gestational diabetes mellitus and women with normal glucose tolerance. Participants will be assigned to either a structured nutrition counseling group or a standard care group according to glucose tolerance status. The counseling program will include education and follow-up on healthy eating during pregnancy, gestational diabetes management, portion control, food choices, meal planning, and cooking methods. Diet quality, dietary habits, biochemical parameters, advanced glycation end products, gestational weight gain, and fetal outcomes will be assessed during follow-up.",[27,86],[140,141,142,143,144],"Advanced Glycation End Products","Diet Quality","Nutrition Counseling","Dietary Habits","Highly Processed Food Consumption","NOT_YET_RECRUITING","2026-06-08",{"date":148,"type":35},"2026-06-09",{"date":150,"type":21},"2026-08",{"date":152,"type":21},"2027-07",{"name":154,"class":68},"Istanbul Saglik Bilimleri University",{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":52,"sex":53,"minAge":162,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":169,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":43},"100500765","gestational-diabetes-and-perinatal-depression-an-intervention-program-100500765","NCT05800509","Gestational Diabetes and Perinatal Depression: an Intervention Program","Gestational Diabetes and Depression in Pregnancy and the Postpartum Period Among Women: A Longitudinal Study and Interventive Program","Inclusion Criteria:\n\n* 1\\. The diagnosis of gestational diabetes mellitus.\n* 2\\. No any history of disease\\* before the pregnancy or do have history of disease\\* without taking any medicines. (\\*disease, eg. hypertension, diabetes mellitus, hyperthyroidism...etc.)\n* 3\\. No recurrent pregnancy loss and stable condition in the first trimester of pregnancy.\n* 4\\. Using smart phone.\n* 5\\. Being willing to participate in this study.\n\nExclusion Criteria:\n\n\\- 1. No diagnosis of diabetes mellitus before pregnancy.","20 Years",{"count":55,"type":21},[24],"Background: The gestational diabetes mellitus and perinatal depression are both global public health issues with high prevalence. Non-perinatal diabetes mellitus and depression are confirmed to have reciprocal influence, which is bidirectional relationship. However, there are still no any confirmations of relationship in the perinatal period. The reason could be that these kinds of studies mostly had been done for postpartum depression, they had rarely been discussed with a clearly sequential influence between gestational diabetes mellitus and perinatal depression. Additionally, there have not been so many Asian countries which been done this kind of studies, therefore, this study will focus on the relationship of gestational diabetes mellitus and perinatal depression.\n\nPurpose: This study will discuss the bidirectional relationship of gestational diabetes mellitus and perinatal depression. In the other words, the prenatal depression influences on gestational diabetes mellitus, and vice versa. Those changeable factors, such as social support, health behavior, prenatal body index, weight gain during pregnancy, perinatal complications…etc, will be tested for whether they could be regulators or not between the gestational diabetes mellitus and perinatal depression.Afterwards, a part of participants with diagnosis of gestational diabetes mellitus will receive the intervention of health education to influence the health behavior, then depression and other obstetrics and gynecological results will be tested for effects.",[27,167,168],"Postpartum Depression","Perinatal Depression",[170,27,168,167,116],"Antepartum Depression","2026-03-19",{"date":173,"type":35},"2026-03-23",{"date":175,"type":35},"2023-10-26",{"date":177,"type":21},"2026-12-31",{"name":125,"class":68},{"id":180,"slug":181,"hasResults":11,"nctId":182,"briefTitle":183,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":190,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":197,"locationsCount":43},"100565899","the-project-for-managing-cardiometabolic-risk-in-women-diagnosed-with-gestational-diabetes-mellitus-100565899","NCT06648174","The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus","The Project for Managing Cardiometabolic Risk in Women Diagnosed With Gestational Diabetes Mellitus: The Development and Application of \"a Lifestyle Intervention Based on Health Belief Model Supported by Mobile Health\"","Inclusion Criteria:\n\n1. Aged 18 years or above\n2. Pregnant women diagnosed with gestational diabetes mellitus\n3. Willing to participate in the study\n\nExclusion Criteria:\n\n1. Diagnosed with diabetes mellitus before pregnancy\n2. Allergic to materials such as tapes (e.g., redness, swelling, itching, pain, blisters, or rashes caused by breathable tapes or patches)\n3. Abnormal coagulation function",{"count":110,"type":21},[24],"This study aims to examine the effects of a lifestyle intervention based on a health belief model (HBM) supported by mobile health (mHealth) and the impact of continuous glucose monitoring (CGM) on maternal glycemic parameters, cardiometabolic risk, health behavior and infant's outcomes among women diagnosed with gestational diabetes mellitus (GDM).",[27,114],[27,114,116],"2026-01-16",{"date":193,"type":35},"2026-01-20",{"date":195,"type":35},"2024-11-11",{"date":123,"type":21},{"name":125,"class":68},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":208,"briefSummary":209,"conditions":210,"keywords":213,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":43},"100549283","a-study-of-the-intervention-of-time-restricted-eating-in-high-risk-populations-of-gdm-100549283","NCT06431997","A Study of the Intervention of Time-restricted Eating in High-risk Populations of GDM","Effects of Time-restricted Eating on the Incidence of Gestational Diabetes Mellitus in High-risk Populations: a Randomized Controlled Study","Inclusion criteria:\n\n1. Aged 18-50 years;\n2. The risk for GDM includes overweight or obesity (BMI ≥ 24 kg\u002Fm2 before pregnancy), first-degree relative with diabetes, history of cardiovascular disease, hypertension (≥130\u002F80 mmHg or on therapy for hypertension), HDL cholesterol level \\\u003C 1 mmol\u002FL and\u002For a triglyceride level \\> 2.8 mmol\u002FL, history of GDM, history of macrosomia delivery, individuals with polycystic ovary syndrome, repeated positive fasting urine glucose in the first trimester, or age\\>45 years according to Guideline of Diagnosis and Treatment of Hyperglycemia in Pregnancy (2022);\n3. Less than 14 weeks of gestation;\n4. Able to read and complete questionnaires in Chinese;\n5. singleton pregnancy.\n\nExclusion criteria:\n\n1. Pregestational diabetes (including diabetes diagnosed before conception; fasting blood glucose ≥ 7.0 mmol\u002FL or HbA1c ≥ 6.5% in the first trimester; typical symptoms of hyperglycemia or hyperglycemic crisis with optional blood glucose ≥ 11.1 mmol\u002FL);\n2. Impaired glucose tolerance (including fasting blood glucose ≥ 5.6 mmol\u002FL or two fasting blood glucose ≥ 5.1 mmol\u002FL in the first trimester);\n3. Current or recent use of drugs that affect glucose metabolism such as metformin, glucocorticoids and Orlistat;\n4. Severe comorbidities (including cardiac diseases, kidney diseases, hepatopathy, autoimmune diseases, uncontrolled thyroid disease, previous or current malignant tumors, etc.);\n5. Fetal malformations or chromosomal abnormalities;\n6. Cervical insufficiency (including ultrasonic cervical length \\\u003C 25 mm before 24 weeks of gestation, history of spontaneous preterm birth at 14-36 weeks of previous pregnancy, or cervical dilation in the past or current pregnancy);\n7. Exercise contraindications (including continuous vaginal bleeding, threatened premature labor, placenta previa, premature rupture of membranes, severe anemia, etc.);\n8. Drug abuse, which refers to the repetitive, heavy use of drugs with dependent characteristics such as narcotic, psychotropic substances, tobacco and alcohol;\n9. Hyperemesis gravidarum, which refers to the severe and persistent nausea and vomiting, unable to eat or eat little that leads to dehydration, ketosis and even acidosis;\n10. On a special or prescribed diet for other reasons;\n11. Eating window\\\u003C10 h.\n\nExit criteria：\n\n1. Failure to comply with or assume the corresponding responsibilities and obligations of the informed agreement;\n2. Pregnant women who terminate their pregnancy before completing GDM diagnosis and screening at 24-28 weeks of pregnancy will automatically withdraw from the group, such as severe fetal malformation, eclampsia, abortion, etc.\n3. Major diseases, such as particularly serious obstetric medical events, malignant tumors, serious cardiovascular and cerebrovascular diseases, brain injuries, paralysis and other major diseases, can not continue to accept this intervention plan and follow-up, and withdraw from the study;\n4. Accidental disability or death caused by non-intervention factors occurred during the study period, and he withdrew from the study;\n5. Subjects are subjectively unwilling to continue to accept the intervention program, and sign the withdrawal agreement to withdraw from the group on a voluntary basis, and decide whether to continue to follow up the pregnancy process and outcome according to the specific contents of the withdrawal statement.","50 Years",{"count":207,"type":21},240,[24],"This is a randomized controlled trial, aiming to investigate whether a time-restricted eating (TRE) can reduce the incidence of gestational diabetes mellitus (GDM) in high-risk pregnant women. Investigators intend to conduct a 3-month randomized controlled study to compare the effects of 10-hour TRE and habitual eating time on GDM .",[27,143,211,212],"Lifestyle Intervention","Randomized Controlled Study",[27,214],"Metabolic Diseases","2025-11-18",{"date":217,"type":35},"2025-11-21",{"date":219,"type":35},"2024-04-17",{"date":221,"type":21},"2026-12",{"name":223,"class":68},"Fudan University",{"id":225,"slug":226,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":43},"100605705","produce-rx-in-high-risk-pregnant-mothers-at-harris-health-100605705","NCT07165990","Produce Rx in High Risk Pregnant Mothers at Harris Health","Inclusion Criteria:\n\n* pregnant women receiving care at Harris Health clinics\n* Medicaid eligible or receiving Medicaid\n* \\\u003C=14 weeks gestation at the time of the first prenatal visit and study enrollment\n* meet the ACOG criteria for early screening for GDM (have a BMI of 30 or greater and at least one additional ACOG-designated risk factor for GDM from the following: Age \\> 35 years; Black, Hispanic, Native American, Asian American or Pacific Islander ethnicity; history of GDM in prior pregnancy; A1c level \\> 5.7 \\& \\\u003C 6.4; history of hypertension, pregnancy hypertension, heart disease, HIV, high triglycerides, polycystic ovarian syndrome; Immediate family member (parent or sibling) has had diabetes)\n* fall within the study delivery radius\n\nExclusion Criteria:\n\n* report existing or pregestational T2DM\n* have hemoglobin A1c\\>=7\n* are prescribed insulin therapy or metformin upon first screening","44 Years",{"count":232,"type":21},400,[24],"The purpose of this study is to assess the effectiveness of a \"Food is Medicine\" (FIM) intervention on incidence of gestational diabetes mellitus (GDM) among pregnant women at risk for GDM within the Harris Health system.",[27],"2025-09-02",{"date":238,"type":35},"2025-09-10",{"date":240,"type":21},"2025-09-08",{"date":242,"type":21},"2026-10-01",{"name":244,"class":68},"The University of Texas Health Science Center, Houston",{"id":246,"slug":247,"hasResults":11,"nctId":248,"briefTitle":249,"officialTitle":249,"acronym":250,"eligibilityCriteria":251,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":254,"briefSummary":255,"conditions":256,"keywords":260,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":43},"100500276","wenzhou-gestational-diabetes-cohort-100500276","NCT05794152","Wenzhou Gestational Diabetes Cohort","WGDC","Inclusion Criteria:\n\n* Women aged 18 years or older\n* Women with GDM mainly at 24-28 weeks of gestation\n* Women intended to deliver at Wenzhou People's Hospital\n* Women intended to remain in Wenzhou with their child for ≥4 years\n\nExclusion Criteria:\n\n* Women with cancer and other serious medical disorders",{"count":253,"type":21},300,[24],"The Wenzhou Gestational Diabetes Cohort (WGDC) is a prospective cohort study among women with gestational diabetes mellitus (GDM) during pregnancy and their offspring living in Wenzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with GDM over 2 weeks, and to facilitate the development of personalized nutritional\u002Flifestyle recommendation among these patients. Another aim of the WGDC is to investigate the association of dietary and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the patients with long-term metabolic health of the women and their offspring.",[27,257,258,259],"Intrauterine Hyperglycemia","Birth Outcome, Adverse","Nutrition, Healthy",[261,262,263],"Precision Nutrition","Host and Microbiome","Birth Outcomes","2025-03-30",{"date":266,"type":35},"2025-04-03",{"date":268,"type":35},"2023-03-21",{"date":270,"type":21},"2033-03-21",{"name":272,"class":68},"Westlake University",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":278,"acronym":279,"eligibilityCriteria":280,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":205,"enrollmentInfo":281,"targetDuration":4,"studyType":22,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":43},"100466064","spark--a-digital-platform-to-improve-self-management-of-gestational-diabetes-100466064","NCT05348863","SPARK- a Digital Platform to Improve Self-management of Gestational Diabetes","SPARK: Smart Phone App for Gestational Diabetes Patients Supporting Key Lifestyle Behaviors and Glucose Control","SPARK","Inclusion Criteria:\n\n* a confirmed diagnosis of GDM detected by oral glucose tolerance test in accordance with the World Health Organization guidelines\n\nExclusion Criteria:\n\n* known pre-pregnancy diabetes\n* twin pregnancy\n* \\\u003C18 years of age\n* severe co-morbidities that would limit participation or a previously diagnosed severe psychiatric illness.",{"count":282,"type":21},360,[24],"Gestational diabetes mellitus (GDM) is an increasing public health challenge. Innovative, effective and scalable lifestyle interventions to support women with GDM to manage their disease and to prevent adverse obstetric and neonatal outcomes as well as later morbidity are requested.The aim of this project is to evaluate whether a novel, mobile health (mHealth) platform (SPARK) can improve self-management of GDM and prevent adverse maternal and offspring outcomes. SPARK is a multi-centre randomised controlled trial recruiting women diagnosed with GDM in South Eastern Sweden. Women will be randomised to the control or intervention group. All women will receive standard care. The intervention group will also receive support through the SPARK platform for healthy eating, physical activity and glycaemic control. Pregnancy outcomes are glycaemic control (primary), diet, physical activity, metabolic and inflammatory biomarkers in gestational week 36-37 as well as adverse obstetric and neonatal outcomes. Secondary outcomes also include cardiometabolic risk, physical activity and healthy eating behaviours one-year postpartum.",[27],"2025-01-17",{"date":288,"type":35},"2025-01-22",{"date":290,"type":35},"2022-10-28",{"date":292,"type":21},"2026-12-30",{"name":294,"class":68},"Karolinska Institutet",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":52,"sex":16,"minAge":162,"maxAge":4,"enrollmentInfo":302,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":304,"conditions":305,"keywords":306,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":43},"100532634","influence-of-chrono-nutrition-factors-and-temporal-dietary-patterns-on-glycemic-parameters-during-pregnancy-100532634","NCT06215352","Influence of Chrono-nutrition Factors and Temporal Dietary Patterns on Glycemic Parameters During Pregnancy.","Influence of Chrono-nutrition Factors, Temporal Dietary Patterns, and Their Interactions With Dietary Quality During Pregnancy on Maternal Gestational Diabetes, Glycemic Parameters, and Gestational Weight Gain.","Inclusion Criteria:\n\n1. Women aged 20 years or older.\n2. Pregnancy duration between 10 and 15 weeks.\n\nExclusion Criteria:\n\n1. Diagnosis of type 1 diabetes, type 2 diabetes, or gestational diabetes.\n2. Currently taking medications that may affect glucose metabolism (e.g., metformin).\n3. Irregular working schedule, such as shift work.\n4. Presence of a multiple pregnancy.",{"count":303,"type":21},316,"This study aims to establish a new cohort study to investigate the relationship between chrono-nutrition factors during pregnancy and maternal GDM (Gestational diabetes mellitus), glycemic parameters, and gestational weight gain.",[27],[307,308,309],"Chrono-nutrition","Gestational diabetes mellitus","Metabolic health","2024-01-23",{"date":312,"type":35},"2024-01-25",{"date":314,"type":35},"2024-01-09",{"date":316,"type":21},"2028-03",{"name":125,"class":68},{"id":319,"slug":320,"hasResults":11,"nctId":321,"briefTitle":322,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":52,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":324,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":326,"conditions":327,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":337,"locationsCount":43},"100523544","research-on-potential-biomarkers-of-prediabetes-and-diabetes-based-on-maldi-tof-ms-platform-100523544","NCT06097065","Research on Potential Biomarkers of Prediabetes and Diabetes Based on MALDI-TOF MS Platform.","Inclusion Criteria:\n\n1. Inclusion criteria for cases:\n\n   Non pregnant people: the remaining fasting serum\u002Fplasma and urine samples of prediabetes\u002Fdiabetes patients (prediabetes: IFG: FPG 6.1-6.9mmol\u002FL, Blood glucose 2h after meal\\\u003C7.8mmol\u002FL（WHO）; IGT: FPG\\\u003C7.0mmol\u002FL, Blood glucose 2h after meal 7.8-11.1mmol\u002FL（WHO）; diabetes: Typical symptoms of diabetes, FPG \\>= 7.0mmol\u002FL or 75g OGTT 2h blood glucose \\>= 11.1mmol\u002FL).\n\n   Pregnant people: the remaining fasting serum\u002Fplasma and urine samples of gestational diabetes patients (75g OGTT test FPG \\>= 5.1mmol\u002FL or 1h blood glucose \\>= 10.0mmol\u002FL or 2h blood glucose \\>= 8.5mmol\u002FL（IADPSG; ADA)).\n2. Inclusion criteria of the controls were as follows:\n\nNon pregnant people: the remaining fasting serum\u002Fplasma and urine samples of normal population for glucose tolerance test (FPG 3.9-6.1mmol\u002FL,75g OGTT test 1h blood glucose 6.7-11.1mmol\u002FL,75g OGTT test 2h blood glucose 3.6-7.8mmol\u002FL).\n\nPregnant people: the remaining fasting serum\u002Fplasma and urine samples of people who do not meet the diagnostic criteria for gestational diabetes (3.9\\\u003C=75g OGTT test FPG\\\u003C5.1mmol\u002FL,6.7 \\\u003C= 1h blood glucose\\\u003C10.0mmol\u002FL,3.6\\\u003C=2h blood glucose\\\u003C8.5mmol\u002FL).\n\n\\-\n\nExclusion Criteria:\n\nCommon exclusion criteria for cases and control were as follows: The sample volume of serum\u002Fplasma\u002Furine is less than 300ul; Improper storage of samples or repeated freezing and thawing; The serum \u002Fplasma has obvious hemolysis, lipemia or jaundice.\n\n\\-",{"count":325,"type":21},2860,"Through the MALDI-TOF MS platform, explore the proteomics and peptidomics differences of fasting serum\u002Fplasma and urine between non pregnant people with normal glucose tolerance test and prediabetes \u002Fdiabetes patients, pregnant people with normal glucose tolerance test and pregnant diabetes patients respectively; To explore the role of its proteomics and peptidomics differences in the diagnosis of prediabetes and diabetes, and to establish a new method of differential diagnosis by using the omics data and key characteristic peaks to find potential new diagnostic markers.",[328,329,27,330],"Prediabetes","Diabetes Mellitus","Proteomics","2023-10-18",{"date":333,"type":35},"2023-10-24",{"date":335,"type":35},"2022-05-20",{"date":177,"type":21},{"name":338,"class":68},"Zhujiang Hospital",{"id":340,"slug":341,"hasResults":11,"nctId":342,"briefTitle":343,"officialTitle":344,"acronym":345,"eligibilityCriteria":346,"healthyVolunteers":52,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":43},"100403176","gdm-and-its-consequences-in-mothers-and-offsprings-100403176","NCT04529889","GDM and Its Consequences in Mothers and Offsprings","Gestational Diabetes Mellitus and Its Consequences in Mothers and Offsprings","GDMCMO","Inclusion Criteria:\n\n1. Pregnant women diagnosed with gestational diabetes mellitus\n2. Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n3. Permanent residents or families intended to remain in Guangzhou with their child for no less than 3 years\n\nExclusion Criteria:\n\n1. Women with pre-gestational diabetes mellitus\n2. Women with chronic hypertension or kidney disease",{"count":348,"type":21},7000,"Gestational diabetes mellitus (GDM) is one of the most common disorders which occured during pregnancy. GDM is not only associated with short-term maternal and fetal adverse outcomes, but also related to a wide range of long-term consequences for both mother and child. The GDM and Its Consequences for mothers and offsprings (GDMCMO) aims to establish a cohort to follow both maternal and offsprings'short-term and long-term outcomes, including fetal malformations including congenital heart diseases, birth weight, preterm birth, caesarean section delivery, body growth and neurodevelopment after birth, obesity, type 2 diabetes and impaired insulin sensitivity and secretion, lung health and allergic diseases later in life for offspring, as well as future type 2 diabetes and cardiovascular risk factors for mother after delivery. Biological samples including blood and tissue samples of mothers and children are also collected during pregnancy and after delivery.",[27,351,352,353,354,262],"Pregnancy Outcome","Neurodevelopment","Immune Development","Childhood Obesity",[356,357,358,359],"Hyperglycaemia","Maternal health","Children","Cohort","2023-09-11",{"date":362,"type":35},"2023-09-13",{"date":364,"type":35},"2012-02-01",{"date":366,"type":21},"2038-12-31",{"name":368,"class":68},"Guangzhou Women and Children's Medical Center",{"id":370,"slug":371,"hasResults":11,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":376,"enrollmentInfo":377,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":145,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":387,"locationsCount":4},"100501691","a-novel-device-for-gestational-diabetes-control-100501691","NCT05812547","A Novel Device for Gestational Diabetes Control","A Novel Device for Gestational Diabetes Control, a Randomized Control Trial","Inclusion Criteria:\n\n1. Gravidas aged 18-45 years\n2. Singleton pregnancy\n3. Diagnosed with GDM in current pregnancy\n4. First visit to high-risk pregnancy clinic is no late than 32 weeks' gestation\n5. Not treated with diabetes-related medications\n\nExclusion Criteria:\n\n\\-\n\nMedications:\n\n1. Insulin and medications for glycemic control\n2. Antipsychotics\n3. Diuretics\n4. Corticosteroids\n5. Oncologic treatment\n\nConditions:\n\n1. Previous diagnosis of diabetes\n2. Renal disease\n3. Hepatic disease\n\nPersonal requirements:\n\n1. Inability to read and understand English\n2. Inability to use a smartphone\n3. Any issues arise with using the Lumen device and application\n4. Aerobic exercise \\> 3 times per week","45 Years",{"count":110,"type":21},[24],"Rationale of the study: Gestational diabetes mellitus (GDM) is very common and the rate of women suffering from it expected to increase in the next years. It is associated with maternal and fetal morbidity and the risk is correlated to the patient's degree of glucose control which can be achieved through a change in lifestyle or medication. Several studies have demonstrated the effectiveness of mobile apps in improving obstetric outcomes in GDM. In addition, the LUMEN device is a breathing device that produces dietary and exercise recommendations based on CO2 levels and improves metabolic parameters in patients with type 2 diabetes. No work has been done on its effectiveness in treating GDM. Aims of the study: Comparison of metabolic outcomes in women with gestational diabetes, with or without the use of LUMEN app. Design: This will be an open label parallel group 1:1 randomized-controlled trial Methods: the investigators will recruit women diagnosed with GDM. The women will be randomized to the intervention arm that will use the LUMEN device and app or to the control arm that will use a free mobile tracking app. The women will be required to monitor their blood sugar levels daily and to have GDM follow-up in the feto-maternal outpatient clinic, as is customary in GDM. After the birth, the maternal and neonatal outcome will be recorded. Based on past research data, a recruitment of 170 is needed to demonstrate a 16.7% decrease in insulin use to balance diabetes, with α = 0.05 and β = 80.",[27],"2023-06-18",{"date":383,"type":35},"2023-06-22",{"date":385,"type":21},"2023-08-01",{"date":60,"type":21},{"name":388,"class":68},"Rambam Health Care Campus",{"id":390,"slug":391,"hasResults":11,"nctId":392,"briefTitle":393,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":43},"100255904","strawberry-candy-twists-as-an-alternative-screen-for-gestational-diabetes-a-prospective-trial-100255904","NCT02610179","Strawberry Candy Twists as an Alternative Screen for Gestational Diabetes: A Prospective Trial","Inclusion Criteria:\n\n* Pregnant\n* 24 to 28 weeks gestation\n* Singleton or twin or triplet gestation\n* Willing to participate in the study\n\nExclusion Criteria:\n\n* Known Type II DM\n* Known Type I DM\n* On oral or injectable corticosteroids\n* 50 gram glucola beverage GCT of greater than or equal to 190 mg\u002Fdl","64 Years",{"count":397,"type":21},617,[24],"The goal of this prospective study is to determine whether there is superiority of 10 Twizzlers to the 50 gram glucola beverage for screening for GDM in a population based study.",[27],"2023-05-09",{"date":403,"type":35},"2023-05-11",{"date":405,"type":35},"2015-04",{"date":407,"type":21},"2027-03",{"name":409,"class":68},"Baylor College of Medicine"]